Dihydrofolate reductase I164L mutations in Plasmodium falciparum isolates: clinical outcome of 14 Kenyan adults infected with parasites harbouring the I164L mutation

Mary J. Hamel, Amanda Poe, Peter Bloland, Andrea McCollum, Zhiyong Zhou, Ya Ping Shi, Peter Ouma, Kephas Otieno, John Vulule, Ananias Escalante, Venkatachalam Udhayakumar, Laurence Slutsker

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Recently, Plasmodium falciparum bearing dihydrofolate reductase (DHFR) I164L was isolated from Africa. Quadruple mutations containing I164L confer high-level resistance to antifolate antimalarials. We prospectively measured the effect of co-trimoxazole (CTX) prophylaxis on P. falciparum antifolate resistance development among HIV-infected persons. HIV-positive patients with CD4 cell count <350 cells/μl (n = 692) received CTX; HIV-positive patients with CD4 cell count ≥350 cells/μl (n = 336) and HIV-negative patients (n = 132) received multivitamins. Malaria microscopy-positive samples (n = 413) and selected microscopy-negative/PCR-positive samples (n = 76) were analysed for DHFR mutations at baseline and during six months follow up. We identified I164L in 14 patients. Seven were malaria microscopy-positive: two failed sulfadoxine-pyrimethamine (SP). Among seven microscopy-negative/PCR-positive patients, none developed patent infections with I164L. I164L was not associated with high-level SP resistance or poor outcome among adults living where malaria is highly endemic. Surveillance to monitor spread of I164L is critical, especially among children and pregnant women, who are potentially a source for I164L amplification.

Original languageEnglish (US)
Pages (from-to)338-345
Number of pages8
JournalTransactions of the Royal Society of Tropical Medicine and Hygiene
Volume102
Issue number4
DOIs
StatePublished - Apr 2008

Fingerprint

Tetrahydrofolate Dehydrogenase
Plasmodium falciparum
Parasites
Microscopy
Mutation
HIV
Malaria
Folic Acid Antagonists
Sulfamethoxazole Drug Combination Trimethoprim
CD4 Lymphocyte Count
Polymerase Chain Reaction
Antimalarials
Pregnant Women
Infection

Keywords

  • DHFR
  • Drug resistance
  • Malaria
  • Mutation
  • Plasmodium falciparum
  • Sulfadoxine-pyrimethamine

ASJC Scopus subject areas

  • Parasitology
  • Medicine(all)

Cite this

Dihydrofolate reductase I164L mutations in Plasmodium falciparum isolates : clinical outcome of 14 Kenyan adults infected with parasites harbouring the I164L mutation. / Hamel, Mary J.; Poe, Amanda; Bloland, Peter; McCollum, Andrea; Zhou, Zhiyong; Shi, Ya Ping; Ouma, Peter; Otieno, Kephas; Vulule, John; Escalante, Ananias; Udhayakumar, Venkatachalam; Slutsker, Laurence.

In: Transactions of the Royal Society of Tropical Medicine and Hygiene, Vol. 102, No. 4, 04.2008, p. 338-345.

Research output: Contribution to journalArticle

Hamel, Mary J. ; Poe, Amanda ; Bloland, Peter ; McCollum, Andrea ; Zhou, Zhiyong ; Shi, Ya Ping ; Ouma, Peter ; Otieno, Kephas ; Vulule, John ; Escalante, Ananias ; Udhayakumar, Venkatachalam ; Slutsker, Laurence. / Dihydrofolate reductase I164L mutations in Plasmodium falciparum isolates : clinical outcome of 14 Kenyan adults infected with parasites harbouring the I164L mutation. In: Transactions of the Royal Society of Tropical Medicine and Hygiene. 2008 ; Vol. 102, No. 4. pp. 338-345.
@article{e84f627b0c1e4e4bbb30cefe4c633dac,
title = "Dihydrofolate reductase I164L mutations in Plasmodium falciparum isolates: clinical outcome of 14 Kenyan adults infected with parasites harbouring the I164L mutation",
abstract = "Recently, Plasmodium falciparum bearing dihydrofolate reductase (DHFR) I164L was isolated from Africa. Quadruple mutations containing I164L confer high-level resistance to antifolate antimalarials. We prospectively measured the effect of co-trimoxazole (CTX) prophylaxis on P. falciparum antifolate resistance development among HIV-infected persons. HIV-positive patients with CD4 cell count <350 cells/μl (n = 692) received CTX; HIV-positive patients with CD4 cell count ≥350 cells/μl (n = 336) and HIV-negative patients (n = 132) received multivitamins. Malaria microscopy-positive samples (n = 413) and selected microscopy-negative/PCR-positive samples (n = 76) were analysed for DHFR mutations at baseline and during six months follow up. We identified I164L in 14 patients. Seven were malaria microscopy-positive: two failed sulfadoxine-pyrimethamine (SP). Among seven microscopy-negative/PCR-positive patients, none developed patent infections with I164L. I164L was not associated with high-level SP resistance or poor outcome among adults living where malaria is highly endemic. Surveillance to monitor spread of I164L is critical, especially among children and pregnant women, who are potentially a source for I164L amplification.",
keywords = "DHFR, Drug resistance, Malaria, Mutation, Plasmodium falciparum, Sulfadoxine-pyrimethamine",
author = "Hamel, {Mary J.} and Amanda Poe and Peter Bloland and Andrea McCollum and Zhiyong Zhou and Shi, {Ya Ping} and Peter Ouma and Kephas Otieno and John Vulule and Ananias Escalante and Venkatachalam Udhayakumar and Laurence Slutsker",
year = "2008",
month = "4",
doi = "10.1016/j.trstmh.2008.01.018",
language = "English (US)",
volume = "102",
pages = "338--345",
journal = "Transactions of the Royal Society of Tropical Medicine and Hygiene",
issn = "0035-9203",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Dihydrofolate reductase I164L mutations in Plasmodium falciparum isolates

T2 - clinical outcome of 14 Kenyan adults infected with parasites harbouring the I164L mutation

AU - Hamel, Mary J.

AU - Poe, Amanda

AU - Bloland, Peter

AU - McCollum, Andrea

AU - Zhou, Zhiyong

AU - Shi, Ya Ping

AU - Ouma, Peter

AU - Otieno, Kephas

AU - Vulule, John

AU - Escalante, Ananias

AU - Udhayakumar, Venkatachalam

AU - Slutsker, Laurence

PY - 2008/4

Y1 - 2008/4

N2 - Recently, Plasmodium falciparum bearing dihydrofolate reductase (DHFR) I164L was isolated from Africa. Quadruple mutations containing I164L confer high-level resistance to antifolate antimalarials. We prospectively measured the effect of co-trimoxazole (CTX) prophylaxis on P. falciparum antifolate resistance development among HIV-infected persons. HIV-positive patients with CD4 cell count <350 cells/μl (n = 692) received CTX; HIV-positive patients with CD4 cell count ≥350 cells/μl (n = 336) and HIV-negative patients (n = 132) received multivitamins. Malaria microscopy-positive samples (n = 413) and selected microscopy-negative/PCR-positive samples (n = 76) were analysed for DHFR mutations at baseline and during six months follow up. We identified I164L in 14 patients. Seven were malaria microscopy-positive: two failed sulfadoxine-pyrimethamine (SP). Among seven microscopy-negative/PCR-positive patients, none developed patent infections with I164L. I164L was not associated with high-level SP resistance or poor outcome among adults living where malaria is highly endemic. Surveillance to monitor spread of I164L is critical, especially among children and pregnant women, who are potentially a source for I164L amplification.

AB - Recently, Plasmodium falciparum bearing dihydrofolate reductase (DHFR) I164L was isolated from Africa. Quadruple mutations containing I164L confer high-level resistance to antifolate antimalarials. We prospectively measured the effect of co-trimoxazole (CTX) prophylaxis on P. falciparum antifolate resistance development among HIV-infected persons. HIV-positive patients with CD4 cell count <350 cells/μl (n = 692) received CTX; HIV-positive patients with CD4 cell count ≥350 cells/μl (n = 336) and HIV-negative patients (n = 132) received multivitamins. Malaria microscopy-positive samples (n = 413) and selected microscopy-negative/PCR-positive samples (n = 76) were analysed for DHFR mutations at baseline and during six months follow up. We identified I164L in 14 patients. Seven were malaria microscopy-positive: two failed sulfadoxine-pyrimethamine (SP). Among seven microscopy-negative/PCR-positive patients, none developed patent infections with I164L. I164L was not associated with high-level SP resistance or poor outcome among adults living where malaria is highly endemic. Surveillance to monitor spread of I164L is critical, especially among children and pregnant women, who are potentially a source for I164L amplification.

KW - DHFR

KW - Drug resistance

KW - Malaria

KW - Mutation

KW - Plasmodium falciparum

KW - Sulfadoxine-pyrimethamine

UR - http://www.scopus.com/inward/record.url?scp=40249118197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40249118197&partnerID=8YFLogxK

U2 - 10.1016/j.trstmh.2008.01.018

DO - 10.1016/j.trstmh.2008.01.018

M3 - Article

C2 - 18321547

AN - SCOPUS:40249118197

VL - 102

SP - 338

EP - 345

JO - Transactions of the Royal Society of Tropical Medicine and Hygiene

JF - Transactions of the Royal Society of Tropical Medicine and Hygiene

SN - 0035-9203

IS - 4

ER -